Tempus xM
Tumor-naive liquid-only MRD assay combining methylation- and variant-based workflows for stage II-III colorectal cancer.
- Developer
- Tempus AI
- Intended use
- Mrd
- Cancer scope
- Not reported
- Specimen
- Peripheral whole blood
- Molecular modality
- DNA methylation, DNA mutation
- Current version
- Tempus xM tumor-naive CRC MRD configuration
- Evidence context
- 0 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.